Annie Tsz Wai Chu

Annie Tsz Wai Chu

Auto-generated profile, based on publicly available information

Annie Tsz Wai Chu

Hong Kong Genome Institute, Hong Kong SAR, China

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 October 2022 in Frontiers in Public Health
Verified
Journal Article
Open access
CCClaudia Ching Yan Chung
Claudia Ching Yan Chung
HPHong Kong Genome Project
Hong Kong Genome Project
ACAnnie Tsz Wai Chu
Annie Tsz Wai Chu
BCBrian Hon Yin Chung
Brian Hon Yin Chung
The genomics revolution over the past three decades has led to great strides in rare disease (RD) research, which presents a major shift in global policy landscape. While RDs are individually rare, there are common challenges and unmet medical and social needs experienced by the RD population globally. The various disabilities arising from RDs as well as diagnostic and treatment uncertainty were demonstrated to have detrimental influence on the health, psychosocial, and economic aspects of RD families. Despite the collective large number of patients and families affected by RDs internationally, the general lack of public awareness and expertise constraints have neglected and marginalized the RD population in health systems and in health- and social-care policies. The current Coronavirus Disease of 2019 (COVID-19) pandemic has exposed the long-standing and fundamental challenges of the RD population, and has reminded us of the critical need of addressing the systemic inequalities and widespread disparities across populations and jurisdictions. Owing to the commonality in goals between RD movements and universal health coverage targets, the United Nations (UN) has highlighted the importance of recognizing RDs in policies, and has recently adopted the UN Resolution to promote greater integration of RDs in the UN agenda, advancing UN's commitment in achieving the 2030 Sustainable Development Goals of “leav[ing] no one behind.” Governments have also started to launch Genome Projects in their respective jurisdictions, aiming to integrate genomic medicine into mainstream healthcare. In this paper, we review the challenges experienced by the RD population, the establishment and adoption of RD policies, and the state of evidence in addressing these challenges from a global perspective. The Hong Kong Genome Project was illustrated as a case study to highlight the role of Genome Projects in enhancing clinical application of genomic medicine for personalized medicine and in improving equity of access and return in global genomics. Through reviewing what has been achieved to date, this paper will provide future directions as RD emerges as a global public health priority, in hopes of moving a step toward a more equitable and inclusive community for the RD population in times of pandemics and beyond.

15 May 2023 in Genetics in Medicine
Verified
Journal Article
Open access
CCClaudia C.Y. Chung
Claudia C.Y. Chung
SHShirley P.Y. Hue
Shirley P.Y. Hue
NNNicole Y.T. Ng
Nicole Y.T. Ng
PDPhoenix H.L. Doong
Phoenix H.L. Doong
ACAnnie T.W. Chu
Annie T.W. Chu
BCBrian Hon Yin Chung
Brian Hon Yin Chung
This meta-analysis aims to compare the diagnostic and clinical utility of exome sequencing (ES) vs genome sequencing (GS) in pediatric and adult patients with rare diseases across diverse populations. A meta-analysis was conducted to identify studies from 2011 to 2021. One hundred sixty-one studies across 31 countries/regions were eligible, featuring 50,417 probands of diverse populations. Diagnostic rates of ES (0.38, 95% CI 0.36-0.40) and GS (0.34, 95% CI 0.30-0.38) were similar (P = .1). Within-cohort comparison illustrated 1.2-times odds of diagnosis by GS over ES (95% CI 0.79-1.83, P = .38). GS studies discovered a higher range of novel genes than ES studies; yet, the rate of variant of unknown significance did not differ (P = .78). Among high-quality studies, clinical utility of GS (0.77, 95% CI 0.64-0.90) was higher than that of ES (0.44, 95% CI 0.30-0.58) (P < .01). This meta-analysis provides an important update to demonstrate the similar diagnostic rates between ES and GS and the higher clinical utility of GS over ES. With the newly published recommendations for clinical interpretation of variants found in noncoding regions of the genome and the trend of decreasing variant of unknown significance and GS cost, it is expected that GS will be more widely used in clinical settings.

18 January 2007 in International Journal of Technology Assessment in Health Care
Verified
Journal Article
Closed access
PDF file
YCYingyao Chen
Yingyao Chen
XQXu Qian
Xu Qian
LJLi Jun
Li Jun
JZJie Zhang
Jie Zhang
ACAnnie Chu
Annie Chu
SSStuart O. Schweitzer
Stuart O. Schweitzer
Objectives: The cost-effectiveness of prenatal diagnosis intervention for Down's syndrome (DS) in China was assessed and evidence-based information for policy makers and providers is presented.Methods: Based on field surveys in four selected cities in China and a literature review, the economic evaluation of prenatal diagnosis for DS from a societal perspective is conducted by cost-effectiveness analysis.Results: In current clinical practice, for a cohort of 10,000 pregnant women, the strategy that delivers karyotyping by chorionic villus sampling (CVS) or amniocentesis (AC) only to those pregnant women 35 years of age and older (maternal age screening strategy) can detect .67 DS births. The strategy that offers the diagnostic test after maternal serum screening with α-fetoprotein and human chorionic gonadotrophin (maternal serum screening strategy) can detect 1.41 DS births. The cost per prevented DS birth by the maternal age screening strategy and maternal serum screening strategy is US$13,091 and US$56,048, respectively. Sensitivity analysis shows that the maternal serum screening strategy can be cost-effective if uptake rate of CVS or AC for patients with positive serum tests increase while the cost of serum screening decreases.Conclusions: Although, in general, serum screening has been found to be more cost-effective than maternal age screening, this appears not to be the case in China. The reasons appear to be low uptake rate of the maternal serum strategy, low uptake rate of CVS or AC, and the high price of serum screening. Our findings are that health system factors concerning technology utilization are important determinants of the technology's efficiency.

14 March 2025 in Journal of Human Genetics
Verified
Journal Article
Open access
PDF file
DTDesiree M. S. Tse
Desiree M. S. Tse
BCBrian H. Y. Chung
Brian H. Y. Chung
HCHong Kong Genetic Counselling Practice Consortium
Hong Kong Genetic Counselling Practice Consortium
HPHong Kong Genome Project
Hong Kong Genome Project
ACAnnie T. W. Chu
Annie T. W. Chu
Genetic counselling plays a crucial role in the genomic era, assisting in disease risk determination, diagnosis and management. The lack of an accredited local training program for genetic counselling in Hong Kong has led to pragmatic on-the-job training and diverse practice models. In view of the needs for enhanced awareness in genomic counselling practices among healthcare professionals, a collaborative effort - the Hong Kong Genetic Counselling Practice Consortium - was initiated to develop genomic medicine in Hong Kong. A thematic analysis of genetic counselling practice across 15 regions was conducted, revealing a broad consistency in the scope of duties, with minor differences due to social and cultural influences. Genetic counsellors generally follow a similar protocol, but some approaches vary. Ethical considerations for genetic counsellors are discussed, highlighting their responsibility towards themselves, colleagues, clients, and society. The scope of practice and code of ethics were developed to highlight the key areas of practice duties; guide the conduct of genetic counsellors; and support local counsellors in their professional training, ultimately contributing to the advancement of genomic science and health benefit of the people of Hong Kong.

27 May 2025 in Communications Medicine
Verified
Journal Article
Open access
PDF file
CCClaudia Ching Yan Chung
Claudia Ching Yan Chung
ACAnnie Tsz Wai Chu
Annie Tsz Wai Chu
BCBrian Hon Yin Chung
Brian Hon Yin Chung
Advances in genomic sequencing (GS) have transformed personalised treatment strategies for genetic diseases across a diverse array of clinical indications, resulting in notable public health progress. However, limited evidence on the broader psychosocial and economic impacts hinders its widespread adoption in healthcare systems. The launch of genome projects offers an opportunity to address the unmet needs of a wide range of genetic diseases. This Perspective examines the multi-dimensional effectiveness of GS and summarises indicators and measurement tools for psychosocial and economic outcomes. It highlights priority areas identified by the Clinical Sequencing Exploratory Research Consortium. Drawing on initiatives such as the Genomics England 100,000 Genomes Project and Australian Genomics initiative, this article showcases best practices in selecting outcome measures for assessing the effectiveness of GS in policy and practice. This Perspective intends to equip future studies with a strategic and sustainable approach for outcome-oriented research within genome projects, facilitating evidence-based clinical implementation of GS in an appropriate, equitable and efficient manner.

5 April 2025 in Human Genomics
Verified
Journal Article
Open access
PDF file
ACAnnie Tw Chu
Annie Tw Chu
SSSamuel Yc Sze
Samuel Yc Sze
DTDesiree Ms Tse
Desiree Ms Tse
CLCheryl Wy Lai
Cheryl Wy Lai
CNCarmen S Ng
Carmen S Ng
JQJianchao Quan
Jianchao Quan
Background: The Hong Kong Genome Project (HKGP) is the first population-wide whole genome sequencing (WGS) programme in Hong Kong and aimed to integrate genomic medicine into the healthcare system. Implementing genetic counselling is essential to help participants understand the genetic basis of diseases and guide informed decision making. We assessed participant experiences during the initial HKGP pilot phase that enrolled patients with undiagnosed diseases and hereditary cancers. Methods: Participants were recruited from three partnering centres at public hospitals during June-September 2023. Participant surveys covered four domains: (1) overall satisfaction, (2) informed consent process, (3) genetic counselling, and (4) attitude towards HKGP. Associations with demographic and socioeconomic characteristics were assessed with multivariable logistic regression. Qualitative feedback was collected in focus group interviews. Results: Among 422 eligible participants, 341 completed the survey (80.8% response) and five focus group interviews were held (21 participants). We found 89.8% [95% CI: 86.1–92.7] were satisfied with their HKGP experience. Almost all felt that HKGP participation could benefit others (86.8% [95% CI: 82.7–90.0]) and advance genomic research in Hong Kong (88.9% [95% CI: 85.0-91.9]). The survey item with the lowest agreement among respondents was feeling that HKGP participation could improve their/child’s medical treatment (73.5% [95% CI: 68.5–78.0]). Those with secondary and tertiary education were less likely to agree genetic counselling was helpful (Odds Ratio [OR]: 0.02 [95% CI: 0.001–0.41]; 0.02 [0.001–0.51]), or the appropriate length of time (OR: 0.12 [95% CI: 0.014–0.81]; 0.11 [0.01–0.91]). Focus group participants cited helping scientific advances and shortening the diagnostic odyssey of future patients as key reasons for participation. Participants hoped for a shorter reporting time of WGS results, additional medical follow-up, and allowing referral of relatives. Conclusions: Participants were overall highly satisfied with the HKGP and genetic counselling experience. Satisfaction levels were comparable to overseas genomic programmes and locally provided healthcare services. Participants’ major concerns on WGS reporting time could be addressed by strengthening the informed consent process to ensure their expectations align with project implementation. Emphasizing the long-term value of genomic research and its potential for personalized treatments may increase participant engagement.